Seeking Alpha

Cowen's Phil Nadeau says that its latest physician survey suggests sales of Regeneron's (REGN...

Cowen's Phil Nadeau says that its latest physician survey suggests sales of Regeneron's (REGN 8.9%) big revenue driver, Eylea, may be slowing. Measuring the uptake of the company's treatment for a leading cause of blindness in the elderly, the number of patients on the drug grew 22% from March to May, compared to 155% growth from January to March. Based on this level of deceleration, Cowen thinks the stock may be rich at these levels.
Comments (1)
  • Plus 122% on a small base is probably less than plus 22% on a much larger base.
    Peter Boyle - long time REGN shareholder
    1 Jun 2012, 04:28 PM Reply Like
DJIA (DIA) S&P 500 (SPY)